{"prompt": "['Tofacitinib', 'A3921284 NON-INTERVENTIONAL STUDY PROTOCOL', 'Amended, 12-December-2018', 'Patients may be withdrawn from the study at any time at their own request, or they may be', 'withdrawn at any time at the discretion of the investigator or sponsor for safety, behavioral,', 'or administrative reasons. In any circumstance, every effort should be made to document', 'subject outcome, if possible. The investigator should inquire about the reason for', 'withdrawal and follow-up with the subject regarding any unresolved adverse events.', 'Reasons why patients may discontinue or be withdrawn from the protocol may include one', 'of the following:', 'Patient is lost to follow-up;', 'Death;', 'Study terminated by sponsor;', 'Withdrawal of consent;', 'If any patient withdraws from the study, and also withdraws consent for disclosure of future', 'information, no further evaluations should be performed, and no additional data should be', 'collected. Pfizer may retain and continue to use any data collected before such withdrawal', 'of consent.', '13.3 Institutional Review Board (IRB)/Independent Ethics Committee (IEC)', 'It is the responsibility of the investigator to have prospective approval of the study protocol,', 'protocol amendments, and informed consent forms, and other relevant documents,', '(e.g., recruitment advertisements), if applicable, from the IRB/IEC. All correspondence', 'with the IRB/IEC should be retained in the Investigator File. Copies of IRB/IEC approvals', 'should be forwarded to Pfizer.', 'The investigator is responsible for protocol, informed consent and report forms approval', 'from ethics committee. Ethics Committees must comply with each country laws and be in a', 'position to protect all patients included in the research.', \"Ethics Committee communications will be recorded in the investigator's record. The\", 'approval copy should be sent to Pfizer.', 'If amendments are required to the protocol, the investigator must notify the ethics', 'committee, obtain re-approval and send a copy to Pfizer.', '13.4', 'Ethical conduct of the study', 'This study will be conducted under the legal requirements as well as the International', 'Ethical Guidelines for Biomedical Research principles (Council for International', 'Organizations of Medical Sciences 2002), the Good Clinical Practice guidelines', '(International Conference on Harmonization 1996) and the Helsinki Statement (World', 'Medical Association 2008).', 'In addition, the study will meet the local regulatory requirements.', 'Page 40 of 64']['Tofacitinib', 'A3921284 NON-INTERVENTIONAL STUDY PROTOCOL', 'Amended, 12-December-2018', '14. MANAGEMENT AND REPORTING OF ADVERSE EVENTS/ADVERSE', 'REACTIONS', '14.1', 'Secondary Data Collection Study - Includes Protocol-Required Human Review', 'of Unstructured Data', 'REQUIREMENTS', 'This study protocol requires human review of patient-level unstructured data;', 'unstructured data refer to verbatim medical data, including text-based descriptions and', 'visual depictions of medical information, such as medical records, images of physician', 'notes, neurological scans, X-rays, or narrative fields in a database. The reviewer is', 'obligated to report adverse events (AE) with explicit attribution to any Pfizer drug that', 'appear in the reviewed information (defined per the patient population and study period', 'specified in the protocol). Explicit attribution is not inferred by a temporal relationship', 'between drug administration and an AE, but must be based on a definite statement of', 'causality by a healthcare provider linking drug administration to the AE.', 'The requirements for reporting safety events on the non-interventional study (NIS)', 'adverse event monitoring (AEM) Report Form to Pfizer Safety are as follows:', 'All serious and non-serious AEs with explicit attribution to any Pfizer drug that', 'appear in the reviewed information must be recorded on the data collection tool and', 'reported, within 24 hours of awareness, to Pfizer Safety using the NIS AEM Report', 'Form, as well as ethics committees and regulatory agencies that require it.', 'Scenarios involving drug exposure, including exposure during pregnancy, exposure', 'during breast feeding, medication error, overdose, misuse, extravasation, lack of', 'efficacy and occupational exposure associated with the use of a Pfizer product must', 'be reported, within 24 hours of awareness, to Pfizer Safety using the NIS AEM', 'Report Form, as well as ethics committees and regulatory agencies that require it.', 'For these safety events with an explicit attribution to or associated with use of,', 'respectively, a Pfizer product, the data captured in the medical record will constitute all', 'clinical information known regarding these adverse events. No follow-up on related', 'adverse events will be conducted.', 'All research staff members will complete the Pfizer requirements regarding training on', 'the following: \"Your Reporting Responsibilities: Monitoring the Safety, Performance', \"and Quality of Pfizer Products (Multiple Languages)' and any relevant Your\", 'Reporting Responsibilities supplemental training. This training will be provided to all', 'research staff members prior to study start. All trainings include a \"Confirmation of', 'Training Certificate\" (for signature by the trainee) as a record of completion of the', 'Page 41 of 64']\n\n###\n\n", "completion": "END"}